tiprankstipranks
Sarepta completes enrollment in the EMERGENE study of SRP-9003
PremiumThe FlySarepta completes enrollment in the EMERGENE study of SRP-9003
1M ago
Arrowhead price target raised to $80 from $60 at H.C. Wainwright
Premium
The Fly
Arrowhead price target raised to $80 from $60 at H.C. Wainwright
2M ago
Sarepta price target lowered to $75 from $80 at H.C. Wainwright
Premium
The Fly
Sarepta price target lowered to $75 from $80 at H.C. Wainwright
2M ago
Arrowhead price target lowered to $45 from $62 at Piper Sandler
PremiumThe FlyArrowhead price target lowered to $45 from $62 at Piper Sandler
2M ago
Sarepta price target lowered to $182 from $200 at Piper Sandler
Premium
The Fly
Sarepta price target lowered to $182 from $200 at Piper Sandler
2M ago
Sarepta price target raised to $217 from $210 at BofA
Premium
The Fly
Sarepta price target raised to $217 from $210 at BofA
2M ago
Sarepta Therapeutics Announces Leadership Change and Equity Deal
PremiumCompany AnnouncementsSarepta Therapeutics Announces Leadership Change and Equity Deal
2M ago
Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments
Premium
The Fly
Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments
2M ago
Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board
Premium
The Fly
Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100